IBD NC 2019
(1) Cancer and mortality in paediatric onset IBD in Denmark and Finland: a population-based study
(20) Suboptimal Energy Intake During Acute, Severe IBD Predicts Quicker Relapse
(19) Clinical effectiveness of golimumab in ulcerative colitis: a prospective multicentre study based on SWIBREG
(18) Therapeutic infliximab thresholds during first year of maintenance therapy in inflammatory bowel disease
(17) Systemic inflammation in pre-diagnostic ulcerative colitis
(16) IBD Home at GHP Stockholm Gastro Center
(15) Comparison of two automated assays and extraction techniques for analyzing fecal calprotectin
(14) Infliximab clearance is decreased in 2nd and 3rd trimesters of pregnancy in inflammatory bowel disease
(13) Anti-TNFα, immunomodulators and treatment failure in pediatric and adolescent patients with Crohn’s disease
(12) VEDOLIZUMAB SHOWS SUPERIOR EFFICACY VERSUS ADALIMUMAB: VARSITY FIRST HEAD-TO-HEAD STUDY OF BIOLOGICS IN ULCERATIVE COLITIS
(11) MECHANISMS FOR PRIMARY NON-RESPONSE AND THERAPEUTIC THRESHOLDS DURING INFLIXIMAB INDUCTION THERAPY IN INFLAMMATORY BOWEL DISEASE
(10) Validation of IBD diagnoses and Montreal Classification defined subgroups of the diseases in Swedish NPR
(9) Causes and Prognosis of Intestinal Failure in Crohn’s Disease: An 18-year Experience
(8) Ustekinumab for Crohn’s disease: A nationwide long-term real-life observational cohort study on Finnish patients
(7) SERUM N-GLYCOMIC BIOMARKERS PREDICT TREATMENT ESCALATION IN INFLAMMATORY BOWEL DISEASE
(6) Genetic/environmental risk factors do not lead to eosinophil activation in healthy twins of IBD patients
(5) Calprotectin binds lectins: a protective function?
(4) FELISA: A Better, quicker and simpler ELISA for fecal calprotectin
(3) PRedicting Outcomes For Crohn’s dIsease using a moLecular biomarkEr: PROFILE trial update
(2) IBD-PRO: A NOVEL APP-BASED COMMUNICATION TOOL FOR PATIENTS WITH ULCERATIVE COLITIS.